Related Experiment Videos
Leptin in relation to prostate cancer and benign prostatic hyperplasia
P Lagiou1, L B Signorello, D Trichopoulos
1Department of Epidemiology and Harvard Center for Cancer Prevention, Harvard School of Public Health, Boston, MA 02115, USA.
International Journal of Cancer
|April 9, 1998
Summary
This study found that serum leptin levels do not substantially impact the risk of developing prostate cancer or benign prostatic hyperplasia (BPH). Further research is needed to fully understand leptin
Area of Science:
- Endocrinology
- Urology
- Oncology
Background:
- Leptin, a hormone regulating energy balance and reproduction, has been investigated for its potential role in various diseases.
- Its involvement in the etiology of prostate cancer and benign prostatic hyperplasia (BPH) remains unclear.
Purpose of the Study:
- To investigate the association between serum leptin levels and the risk of prostate cancer.
- To examine the relationship between serum leptin levels and benign prostatic hyperplasia (BPH).
Main Methods:
- Serum leptin levels were compared between 43 prostate cancer cases, 41 BPH patients, and 48 healthy controls.
- Multiple logistic regression analysis was employed, adjusting for age, BMI, and various hormone levels.
- Odds ratios (OR) per 4 ng/ml leptin increment were calculated for prostate cancer and BPH.
Main Results:
- The odds ratio for prostate cancer per 4 ng/ml leptin increment was 0.70 (95% CI: 0.32, 1.55).
- The odds ratio for BPH per 4 ng/ml leptin increment was 1.06 (95% CI: 0.67, 1.67).
- Serum leptin levels showed no significant correlation with other measured hormones after adjusting for BMI.
Conclusions:
- Leptin levels are unlikely to substantially influence the risk of developing prostate cancer.
- Leptin levels do not appear to significantly affect the risk of benign prostatic hyperplasia (BPH).